Age, pain intensity, and opioid dose in patients with advanced cancer

被引:0
|
作者
Viganó, A
Bruera, E
Suarez-Almazor, ME [1 ]
机构
[1] Univ Alberta, Healthcare Qual & Outcomes Res Ctr, Heritage Med Res Ctr 214, Dept Med, Edmonton, AB T6G 2S2, Canada
[2] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada
[3] Univ Alberta, Div Palliat Care Med, Edmonton, AB, Canada
[4] Univ Alberta, Grey Nuns Hosp, Div Palliat Care Med, Edmonton, AB, Canada
关键词
age; cancer pain; incidental pain; neuropathic pain; opioid consumption;
D O I
10.1002/(SICI)1097-0142(19980915)83:6<1244::AID-CNCR26>3.3.CO;2-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Elderly patients are more likely to be affected by the acute and chronic toxicities of opioids, but an association between age and long term opioid consumption has not been established clearly in patients with advanced cancer. METHODS. The computerized records of 197 cancer patients admitted to a palliative care unit in Edmonton, Alberta, Canada were examined. The authors examined: demographics (age, gender, and location of primary tumor), pain characteristics (presence of neuropathic pain and incidental pain), mean daily pain intensity (MDPI), and daily opioid consumption measured as (parenteral) morphine equivalent daily dose (MEDD). MDPI and MEED were assessed on Days 2 and 7 after admission, on the day of maximum opioid consumption, and on the day of maximum pain intensity during admission. Average values for MDPI and MEDD were calculated between Days 2 and 7. RESULTS. When age was treated as a categoric variable (< 65 years, 65-74 years, and 75 + years), statistically significant differences in MEDD were observed for age for all estimates except those for Day 7, with older patients requiring a lower equianalgesic dose. No major differences were observed for pain intensity and for the presence of incidental or neuropathic pain across the different age groups, In the multivariate analysis, the reduction in MEDD ranged between 27-71 mg when patients age greater than or equal to 75 years were compared with younger adults. A MEDD increase that ranged between 82-137 mg was associated with the presence of neuropathic pain. CONCLUSIONS. The current study suggests that elderly cancer patients may experience a similar level of pain intensity but require a lower amount of opioid analgesia than younger adults. However, because elderly patients are more likely to be affected by the acute and chronic toxicities of opioids, opioids should be initially administered at a lower dose and titrated cautiously in these patients. (C) 1998 American Cancer Society.
引用
收藏
页码:1244 / 1250
页数:7
相关论文
共 50 条
  • [41] Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment
    Jui-Hung Tsai
    I-Ting Liu
    Pei-Fang Su
    Ying-Tzu Huang
    Ge-Lin Chiu
    Yu-Yeh Chen
    Wei-Shu Lai
    Peng-Chan Lin
    BMC Palliative Care, 22
  • [42] Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment
    Tsai, Jui-Hung
    Liu, I-Ting
    Su, Pei-Fang
    Huang, Ying-Tzu
    Chiu, Ge-Lin
    Chen, Yu-Yeh
    Lai, Wei-Shu
    Lin, Peng-Chan
    BMC PALLIATIVE CARE, 2023, 22 (01)
  • [43] Management of cancer pain in advanced cancer patients
    Bisht, M.
    Dhasmana, D. C.
    Saini, S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 232 - 232
  • [44] Associations between Heat Pain Perception and Opioid Dose among Patients with Chronic Pain Undergoing Opioid Tapering
    Hooten, W. Michael
    Mantilla, Carlos B.
    Sandroni, Paola
    Townsend, Cynthia O.
    PAIN MEDICINE, 2010, 11 (11) : 1587 - 1598
  • [45] A survey of pain in patients with advanced cancer
    Twycross, R
    Harcourt, J
    Bergl, S
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1996, 12 (05) : 273 - 282
  • [46] Age-dependent opioid escalation in chronic pain patients
    Buntin-Mushock, C
    Phillip, L
    Moriyama, K
    Palmer, PP
    ANESTHESIA AND ANALGESIA, 2005, 100 (06): : 1740 - 1745
  • [47] FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC)
    Vary, A.
    Lebellec, L.
    Le Deley, M-C.
    Penel, N.
    Cheymol, C.
    Rad, E.
    El Hajbi, F.
    Edeline, J.
    Di Fiore, F.
    Bimbai, A-M.
    Turpin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S942 - S943
  • [48] The efficacy of low dose transdermal fentanyl in opioid-naive cancer patients with moderate and severe pain
    Song, H.
    Kang, M.
    Kang, J.
    Oh, S.
    Hwang, I.
    Lee, S.
    Kim, W.
    Park, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S278 - S279
  • [49] Insurance company denial of payment and enforced changes in the type and dose of opioid analgesics for patients with cancer pain
    Tanco, Kimberson
    Bruera, Sofia E.
    Bruera, Eduardo
    PALLIATIVE & SUPPORTIVE CARE, 2014, 12 (06) : 515 - 518
  • [50] Opioid rotation in patients with cancer pain - A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine
    Bruera, E
    Pereira, J
    Watanabe, S
    Belzile, M
    Kuehn, N
    Hanson, J
    CANCER, 1996, 78 (04) : 852 - 857